Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Long-Term Deferred Tax (2020 - 2022)

Unicycive Therapeutics filings provide 2 years of Long-Term Deferred Tax readings, the most recent being $7.4 million for Q4 2022.

  • On a quarterly basis, Long-Term Deferred Tax rose 141.02% to $7.4 million in Q4 2022 year-over-year; TTM through Dec 2022 was $7.4 million, a 141.02% increase, with the full-year FY2022 number at $7.4 million, up 141.02% from a year prior.
  • Long-Term Deferred Tax hit $7.4 million in Q4 2022 for Unicycive Therapeutics, up from $3.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $7.4 million in Q4 2022 to a low of $3.1 million in Q4 2021.